Newly approved pancreatic cancer drug shows promise in lung cancer

Live updates

1. 29d ago

   Surufatinib and Immunotherapy Trial Targets Aggressive Lung Cancer

   A phase 2a study published in Holistic Integrative Oncology indicates that combining an oral targeted drug with standard immunotherapy during maintenance may extend disease-free survival for extensive-stage small cell lung cancer patients. This follows earlier phase 3 trial data establishing tambotatug pelitecan as a new second-line treatment for relapsed small-cell lung cancer. Meanwhile, medical discussions continue regarding personalized cancer vaccines for melanoma developed by Moderna and Merck. Extensive-stage small cell lung cancer persists as a highly lethal malignancy with historically limited treatment options.

   Why it matters

   Extensive-stage small cell lung cancer presents severe clinical challenges with few effective interventions available for patients. Exploring maintenance therapy combinations aims to delay disease progression following initial treatments. This research builds upon recent advancements in antibody-drug conjugates and multi-cancer early detection screenings.

   What is confirmed

   • Extensive-stage small cell lung cancer remains among the most lethal malignancies in medicine.

   Still unconfirmed

   • Adding an oral targeted drug to standard immunotherapy during the maintenance phase may extend the time patients remain free of disease.

   What to watch next

   • Further phase progression and survival data from the surufatinib and immunotherapy maintenance study.
   • Additional clinical trial updates regarding personalized cancer vaccines for melanoma.
   Sources used for this update (2)

   1. Bioengineer.org — Surufatinib Plus Immunotherapy Shows Promise as Maintenance Therapy for Aggressive Lung Cancer
   2. ca.style.yahoo.com — A New Cancer Vaccine Shows Promise for Melanoma—Here’s What Doctors Know So Far
   confidence 80%
2. 30d ago

   Tambotatug Pelitecan emerges as second-line small-cell lung cancer treatment

   Phase 3 trial data establish tambotatug pelitecan as a new second-line treatment for patients with relapsed small-cell lung cancer. This antibody-drug conjugate provides a new option for a patient group that previously had few treatment alternatives. Separately, the PATHFINDER 2 study found that adding a single blood draw screening for over 50 cancers to standard protocols substantially increased detection rates, identifying malignancies that typically remain undetected until later stages.

   Why it matters

   Small-cell lung cancer often requires second-line options after initial treatments fail. These developments follow a trend of diversifying lung cancer care, including the use of AI in drug discovery and the PAPILLON trial's combination of chemotherapy and amivantamab.

   What is confirmed

   • Tambotatug pelitecan is a new second-line treatment for relapsed small-cell lung cancer based on Phase 3 trial data.
   • A single blood draw screening for more than 50 cancers increased detection when used alongside standard screening.

   What to watch next

   • Regulatory approval timelines for tambotatug pelitecan
   • Clinical adoption rates for the PATHFINDER 2 blood test
   Sources used for this update (3)

   1. medicalxpress.com — PATHFINDER 2 findings advance multi-cancer early detection blood testing
   2. www.miragenews.com — Pathfinder 2 Boosts Multi-Cancer Blood Test Detection
   3. www.nature.com — An antibody–drug conjugate for small-cell lung cancer
   confidence 100%
3. 32d ago

   AI-Driven Approach Advances Drug Discovery Following PAPILLON Trial

   Researchers have advanced lung cancer drug discovery by utilizing up to 37,000 AI agents reporting to a chief scientist to develop a promising treatment. This follows previous clinical achievements in the field, highlighted by the PAPILLON trial, which combined amivantamab and chemotherapy to treat rare lung cancers. The PAPILLON trial established a new standard of care by achieving the longest median overall survival to date for its specific patient group. Meanwhile, the innovative AI-driven method points toward an ongoing industry shift toward automated drug discovery processes.

   Why it matters

   Automated and artificial intelligence-driven systems are increasingly shaping pharmaceutical research and development. These technological shifts build on established clinical trial benchmarks, such as combination therapies that improve survival outcomes in hard-to-treat patient populations. Understanding these developments requires tracking both clinical trial efficacy and the integration of large-scale agent systems in research workflows.

   What is confirmed

   • Researchers created a virtual biotech system using up to 37,000 AI agents reporting to a chief scientist to discover a promising drug for lung cancer.
   • The PAPILLON trial established a new standard of care by achieving the longest median overall survival to date for its specific patient group through a combination of amivantamab and chemotherapy.

   What to watch next

   • Further clinical data releases from the AI-discovered lung cancer treatments
   • Peer-reviewed studies detailing the performance of the 37,000 AI agent system
   Sources used for this update (7)

   1. jen.jiji.com — Drones over Copenhagen during Nato summit, area around US embassy closed
   2. jen.jiji.com — Flight chaos in UK, preliminary investigation concluded: no sabotage but a 'one-millisecond' software error
   3. jen.jiji.com — Serie A, today Roma-Inter - Live
   4. jen.jiji.com — Houthi launch attacks against sensitive sites in Riyadh and oil facilities in Yanbu, Saudi Arabia
   5. jen.jiji.com — They manufactured Molotov cocktails and tested them in a warehouse, searches and seizures for four very young people - Video
   6. finance.yahoo.com — CEO Chat with Dr. Christopher Burns, Chief Executive Officer and Managing Director of Amplia Therapeutics – OTC Markets Life Sciences Virtual Investor Forum
   7. www.today.com — The Surprising Clues Your Feet May Reveal About Your Health
   confidence 100%
4. 36d ago

   AI Agents Identify Promising Lung Cancer Drug Candidate

   Researchers created a virtual biotech system using up to 37,000 AI agents reporting to a chief scientist to discover a promising drug for lung cancer. This development follows previous clinical successes in the field, such as the PAPILLON trial's combination of amivantamab and chemotherapy for rare lung cancers. While the PAPILLON trial established a new standard of care by achieving the longest median overall survival to date for its specific patient group, the new AI-driven approach represents a shift toward automated drug discovery.

   Why it matters

   Drug discovery typically requires years of manual laboratory research and high capital investment. Using a swarm of AI agents to simulate biotech operations could accelerate the identification of viable candidates. This occurs alongside efforts like ClearNote Health's use of 5hmC signatures to monitor pancreatic cancer treatments.

   What is confirmed

   • Researchers developed a virtual biotech composed of up to 37,000 agents reporting to a chief scientist.
   • The PAPILLON trial found that combining amivantamab with chemotherapy provides durable clinical benefit for a rare form of lung cancer.

   What to watch next

   • Clinical trial results for the drug discovered by the AI agents
   • Peer review of the virtual biotech methodology
   Sources used for this update (3)

   1. jen.jiji.com — Hemoglobinopathies, the Mediterranean Network is born to improve management
   2. jen.jiji.com — Germany, Klopp against AfD: "Let's not leave national pride to the wrong people"
   3. www.nature.com — How a team of AIs discovered a promising lung-cancer drug
   confidence 100%
5. 37d ago

   PAPILLON trial confirms longest median overall survival for rare lung cancer subset

   Final results from the PAPILLON trial confirm that combining amivantamab with chemotherapy provides durable clinical benefit for a rare, difficult-to-treat form of lung cancer. This combination has achieved the longest median overall survival reported to date for patients with this specific disease. The findings solidify a change in the standard of care for this patient population. Other recent oncology developments include ClearNote Health presenting data on 5hmC signatures for pancreatic cancer treatment monitoring at the AACR Conference on Pancreatic Cancer.

   Why it matters

   Previous reports indicated improved outcomes for lung cancer mutations, specifically EGFR exon 20 insertions and HER2-mutant non-small cell lung cancer. These developments follow earlier data on Daraxonrasib for treatment-resistant cases. The PAPILLON trial specifically targets a rare subset of the disease.

   What is confirmed

   • Amivantamab combined with chemotherapy provides durable clinical benefit and the longest median overall survival reported to date for a rare form of lung cancer.
   • The PAPILLON trial results changed the standard of care for this specific lung cancer subset.
   • ClearNote Health is presenting data for its Avantect Pancreatic Cancer Test and Virtuoso platform at the AACR Conference on Pancreatic Cancer.

   What to watch next

   • Further clinical data on HER2-mutant non-small cell lung cancer following the DESTINY-Lung04 trial
   Sources used for this update (5)

   1. www.news-medical.net — Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer
   2. jen.jiji.com — Leonardo Maria del Vecchio, peace made with Sara Soldati: "We are raising our daughter together"
   3. www.labiotech.eu — Oncology biotech news: key moves to watch in September 2026
   4. pancan.org — PanCAN Announces 2026 Research Grant Recipients
   5. finance.yahoo.com — ClearNote Health to Showcase Power of 5hmC Signatures for Treatment Monitoring at AACR Conference on Pancreatic Cancer
   confidence 100%
6. 40d ago

   Lung cancer treatments show survival gains at 2026 WCLC conference

   New clinical data from the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer indicates improved outcomes for specific lung cancer mutations. Amivantamab combined with chemotherapy showed numerically longer overall survival for patients with EGFR exon 20 insertion mutations in the PAPILLON study. Additionally, trastuzumab deruxtecan significantly improved progression-free survival for those with HER2-mutant non-small cell lung cancer compared to pembrolizumab and platinum-based chemotherapy, according to the DESTINY-Lung04 trial. These findings complement previous reports on Daraxonrasib's potential for treatment-resistant cases.

   Why it matters

   Targeting specific genetic mutations allows for personalized therapies in non-small cell lung cancer. This shift follows the approval of Daraxonrasib for pancreatic cancer, which targets previously undruggable RAS proteins. Recent trends also show a resurgence in mRNA-based cancer vaccines.

   What is confirmed

   • The phase 3 PAPILLON study associated first-line amivantamab plus carboplatin-pemetrexed with numerically longer overall survival in untreated advanced NSCLC patients with EGFR exon 20 insertion mutations.
   • The phase 3 DESTINY-Lung04 trial found first-line trastuzumab deruxtecan significantly improved progression-free survival in patients with advanced or metastatic HER2-mutant NSCLC compared to pembrolizumab plus platinum-based chemotherapy.

   What to watch next

   • FDA approval status for amivantamab-chemotherapy in EGFR Ex20ins cases
   • Insurance coverage updates for Daraxonrasib
   • Phase 3 results for personalized mRNA-based cancer vaccines from Moderna and Merck
   Sources used for this update (5)

   1. jen.jiji.com — MotoGp, today qualifying and Sprint race in Misano: times and where to watch them on TV
   2. jen.jiji.com — Formula 1, today Madrid GP qualifiers: schedule and where to watch them
   3. www.biospace.com — After a brief storm of political headwinds, mRNA is back with strong momentum
   4. medicalxpress.com — Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation
   5. medicalxpress.com — First-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant lung cancer
   confidence 100%
7. 42d ago

   Daraxonrasib shows promise for lung cancer following pancreatic approval

   Daraxonrasib, marketed as Rasonque, is demonstrating early trial success in treating lung cancer after receiving FDA approval for metastatic pancreatic cancer. The drug targets RAS proteins to treat tumors previously considered undruggable. In pancreatic cancer cases, the medication doubled median survival compared to chemotherapy. While showing potential for treatment-resistant lung cancer, patients still face delays in accessing the therapy because insurance coverage has not kept pace with federal approval.

   Why it matters

   RAS mutations are common drivers of various cancers but have historically been difficult to target with medication. The ability of one drug to address multiple mutation-driven cancers could expand treatment options for patients who fail standard chemotherapy.

   What is confirmed

   • Daraxonrasib is FDA-approved for the treatment of metastatic pancreatic cancer.
   • Daraxonrasib is marketed under the brand name Rasonque.
   • Early trials show daraxonrasib may be effective in treating lung cancer.

   Still unconfirmed

   • Daraxonrasib doubled median survival versus chemotherapy in metastatic pancreatic cancer patients.

   What to watch next

   • Results from expanded lung cancer clinical trials
   • Updates on insurance coverage timelines for Rasonque
   Sources used for this update (5)

   1. jen.jiji.com — Yemen, Houthi rebels advance on the Red Sea: Dhubab and Perim island fall
   2. www.yahoo.com — A New Drug Takes Aim At One Of Cancer’s Most Difficult Targets
   3. www.medicalnewstoday.com — Pancreatic cancer drug may also help fight treatment-resistant lung cancer
   4. www.today.com — How to Reset Your Routine for Fall to Create Healthy Habits
   5. www.ibtimes.com.au — Ozempic and Wegovy Tied to Nearly 40% Fewer Asthma Attacks, UK Records Study Finds
   confidence 90%
8. 43d ago

   Rasonque shows potential for lung cancer treatment despite insurance delays

   Rasonque, a newly FDA-approved pancreatic cancer drug from Revolution Medicines, is showing early trial success in shrinking lung tumors by targeting a wide range of RAS mutations. While the medication targets proteins previously considered undruggable, patients face significant administrative hurdles. Insurance coverage is currently taking weeks to catch up with the federal approval, delaying access to the therapy for those who need it.

   Why it matters

   The drug, known generically as daraxonrasib, represents a technical shift in oncology by attacking RAS mutations. Its success in pancreatic cancer has opened the door for potential approvals across other cancer types.

   What is confirmed

   • The FDA approved Rasonque, generically known as daraxonrasib, for the treatment of pancreatic cancer.
   • Revolution Medicines developed Rasonque to target proteins previously considered undruggable.

   What to watch next

   • Updates on insurance coverage timelines for daraxonrasib
   • Clinical trial results for Rasonque in lung cancer patients
   • FDA approval status for non-pancreatic cancer indications
   Sources used for this update (4)

   1. www.boisestatepublicradio.org — Idaho Matters Doctor Roundtable: September 9, 2026
   2. www.ibtimes.co.uk — Experimental AI-Designed Drug Appears To Reverse Biological Age by up to Six Years in Small Human Trial
   3. jen.jiji.com — Champions League, today Fenerbahce-Roma - Live
   4. jen.jiji.com — Fuel prices, Council of Ministers approves 7-day extension of excise duty cut
   confidence 100%
9. 45d ago

   Revolution Medicines Drug Faces Insurance Hurdles After Approval

   Patients prescribed the newly approved pancreatic cancer treatment Rasonque from Revolution Medicines face delays as insurance coverage takes weeks to catch up following the FDA greenlight. The drug, known generically as daraxonrasib, successfully targets proteins previously considered undruggable and offers hope for future approvals across various cancer types. While early trial data indicate the medication also shrinks lung tumors by targeting a broad range of RAS mutations, patients currently encounter administrative barriers before they can access the therapy.

   Why it matters

   Revolution Medicines seeks to expand the application of daraxonrasib to treat metastatic non-small cell lung cancer after findings appeared in the New England Journal of Medicine. Researchers Salman Punekar and Ron DePinho previously noted that the treatment initiates a new era for RAS-mutant forms of the disease. The success of the drug opens pathways for additional Ras-inhibitor candidates targeting multiple cancer varieties.

   What is confirmed

   • Patients learned it can take insurance coverage weeks to catch up after Rasonque won FDA approval.
   • Rasonque is a pancreatic cancer drug developed by Revolution Medicines.
   • The drug successfully targets undruggable proteins.

   What to watch next

   • Resolution of insurance coverage delays for patients seeking Rasonque
   • Updates on Revolution Medicines seeking to expand drug applications to metastatic non-small cell lung cancer
   Sources used for this update (7)

   1. www.statnews.com — A breakthrough pancreatic cancer drug won approval. They still struggle to access it
   2. www.chemistryworld.com — US approves pancreatic cancer treatment that targets ‘undruggable’ proteins
   3. jen.jiji.com — France, Renoir Museum theft carried out by professionals: 2 paintings in the hands of thieves
   4. www.mycentraloregon.com — New drug shows promise in reducing COPD symptoms in smokers, clinical trials show
   5. www.nbcnews.com — Mother speaks out after family exposed to rabid goats at petting zoo party
   6. www.nbcnews.com — Families in Nebraska say state is taking away vital Medicaid funds from disabled people
   7. www.today.com — See Al Roker and Dylan Dreyer ‘Buddy Up’ at an Aerial Yoga Studio
   confidence 100%
10. 48d ago

    Pancreatic Drug Daraxonrasib Shows Promise in Lung Cancer

    The targeted cancer treatment daraxonrasib, previously approved for metastatic pancreatic cancer, demonstrates potential in shrinking tumors among patients with lung cancer. Early trial data indicate the drug targets a broad range of RAS mutations through a novel mechanism. Revolution Medicines is actively seeking to expand the application of the medication to treat metastatic non-small cell lung cancer following findings published in the New England Journal of Medicine. Researchers Salman Punekar and Ron DePinho highlight the treatment as marking a new era for RAS-mutant forms of the disease, according to recent scientific commentary.

    Why it matters

    Revolution Medicines secured prior approval for daraxonrasib under the brand name Rasonque for pancreatic cancer patients. Investigators are now testing whether the targeted therapy can successfully treat other oncology indications, such as non-small cell lung cancer, which often features difficult RAS mutations. The therapy utilizes a novel mechanism to target these mutations.

    What is confirmed

    • Daraxonrasib is a newly approved drug for pancreatic cancer that shows potential in shrinking tumors in lung cancer patients.
    • The drug targets a broad range of RAS mutations with a novel mechanism.
    • New trial results indicate that daraxonrasib might also be beneficial for some patients with lung cancer.

    What to watch next

    • Regulatory decisions by the FDA regarding the expansion of daraxonrasib to treat lung cancer patients
    • Further Phase 1/2 clinical trial data releases published in the New England Journal of Medicine
    Sources used for this update (4)

    1. www.yahoo.com — Breakthrough Pancreatic Cancer Drug Shows Promise In Lung Cancer Trial
    2. jen.jiji.com — Ostia, blood on the street after the murder-suicide three days ago: residents in shock
    3. oncodaily.com — Salman Punekar and Ron DePinho: Daraxonrasib Marks a New Era for RAS-Mutant Non-Small Cell Lung Cancer
    4. www.ibtimes.com.au — Pancreatic Cancer Drug Daraxonrasib Shows Early Promise Shrinking Tumors In Lung Cancer Trial
    confidence 90%
11. 49d ago

    FDA-Approved Pancreatic Cancer Drug Rasonque Shows Promise for Lung Cancer

    The FDA has approved daraxonrasib, marketed as Rasonque by Revolution Medicines, for the treatment of metastatic pancreatic cancer. Early clinical data now suggest the drug may also be effective against metastatic non-small cell lung cancer. A Phase 1/2 clinical trial published in the New England Journal of Medicine indicates the drug can shrink tumors in patients with this specific type of lung cancer. While the drug is already approved for pancreatic use, Revolution Medicines is seeking to extend its application to lung cancer patients.

    Why it matters

    Rasonque is part of a class of RAS inhibitors targeting mutations common in several aggressive cancers. The drug's approval for pancreatic cancer followed a landmark trial led by Dana-Farber. Its potential expansion into lung cancer treatment could broaden the utility of the medication for a wider patient population.

    What is confirmed

    • The FDA approved daraxonrasib for metastatic pancreatic cancer.
    • Revolution Medicines markets daraxonrasib under the brand name Rasonque.
    • Phase 1/2 clinical data for Rasonque in metastatic non-small cell lung cancer were published in the New England Journal of Medicine.
    • Early studies suggest Rasonque may be effective in treating lung cancer.

    Still unconfirmed

    • The drug costs $480,000 a year.
    • The pancreatic cancer approval followed a landmark clinical trial led by Dana-Farber.

    What to watch next

    • FDA decision on expanding the Rasonque label to include non-small cell lung cancer
    • Publication of further clinical trial data regarding tumor shrinkage rates in lung cancer patients
    Sources used for this update (14)

    1. The New York Times — A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
    2. ABC News - Breaking News, Latest News and Videos — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
    3. Yahoo Finance — New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
    4. News-Medical — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
    5. NBC News — Newly approved pancreatic cancer drug shows promise in lung cancer
    6. jen.jiji.com — School, new Coop campaign launched, focus on circular health
    7. jen.jiji.com — Back to school: ISS mini-guide for parents and children against anxiety
    8. abc7ny.com — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
    9. www.today.com — How New Tech is Helping Aging Adults Stay in Their Home
    10. www.today.com — Surgeon Shares Latest in Prostate Cancer Treatments
    11. www.medpagetoday.com — Rare Brain Disorder Gets Its First FDA Drug Approval
    12. www.medpagetoday.com — Alcohol-Linked Cancer Deaths Rising
    confidence 95%